Mersana Therapeutics

Biotech

GSK inks $1.3B biobucks deal for Mersana’s preclinical ADC

GSK has paid out $100 million cash to Mersana Therapeutics for the potential to add a second antibody-drug conjugate (ADC) to its pipeline.
Gabrielle Masson Aug 8, 2022 4:02pm

J&J's Janssen joins Mersana ADC collabs in $1B biobucks pact

Feb 3, 2022 7:00am

FDA lifts clinical hold from Mersana’s breast cancer trial

Sep 17, 2018 9:20am

Patient death prompts FDA hold on Mersana’s lead cancer ADC

Jul 20, 2018 9:09am

Chutes & Ladders—Andrew Witty shifts to PBM as Optum's CEO

Mar 16, 2018 4:02am

Mersana takes IPO plunge, seeking $75M for its cancer ADCs

Jun 2, 2017 7:34am